Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Chembiochem : a European Journal of Chemical Biology|October 3, 2003
Oligonucleotide-based knockdown technologies: antisense versus RNA interferenceTatjana V Achenbach, Bodo Brunner, Kathrin HeermeierThe Journal of Toxicological Sciences|March 21, 2014
Pau d'arco activates Nrf2-dependent gene expression via the MEK/ERK-pathwayMichelle Richter, Angelika F Winkel, Dietmar Schummer, et al.Molecular Metabolism|January 19, 2019
The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approachSuryaprakash Raichur, Bodo Brunner, Maximilian Bielohuby, et al.Journal of Medicinal Chemistry|October 12, 2022
Small Interfering RNAs Containing Dioxane- and Morpholino-Derived Nucleotide Analogues Show Improved Off-Target Profiles and Chirality-Dependent <i>In Vivo</i> Knock-DownArmin Hofmeister, Kerstin Jahn-Hofmann, Bodo Brunner, et al.Molecular Metabolism|November 8, 2016
Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in miceSebastian Brachs, Angelika F Winkel, Hui Tang, et al.Plos One|February 17, 2017
Correction: Chronic Activation of Hepatic Nrf2 Has No Major Effect on Fatty Acid and Glucose Metabolism in Adult MiceSebastian Brachs, Angelika F Winkel, James Polack, et al.Plos One|November 5, 2016
Chronic Activation of Hepatic Nrf2 Has No Major Effect on Fatty Acid and Glucose Metabolism in Adult MiceSebastian Brachs, Angelika F Winkel, James Polack, et al.Frontiers in Endocrinology|September 28, 2020
Liver-Specific Knockdown of Class IIa HDACs Has Limited Efficacy on Glucose Metabolism but Entails Severe Organ Side Effects in MiceNicole Ziegler, Suryaprakash Raichur, Bodo Brunner, et al.Journal of Medicinal Chemistry|May 5, 2021
Syntheses of Morpholine-Based Nucleotide Analogs for Hepatic siRNA Targeting and StabilizationArmin Hofmeister, Kerstin Jahn-Hofmann, Bodo Brunner, et al.Molecular Pharmaceutics|January 14, 2021
Nanobody-siRNA Conjugates for Targeted Delivery of siRNA to Cancer CellsOleksandr Zavoiura, Bodo Brunner, Peter Casteels, et al.Pageof 2